RECOVERY (Tocilizumab)
Tocilizumab in COVID-19
Patient / Population Intervention / Exposition Vergleich Endpunkt
In 4,116 hospitalised hypoxic patients with COVID-19 and inflammation, tocilizumab reduced 28-day mortality compared with usual care.
N
4.116
Design
Adaptive platform RCT, UK
Endpunkt
28-day all-cause mortality
Relevanz
2
Ergebnis31% vs 35% (RR 0.85). Combined with dexamethasone in most patients.
RECOVERY Collaborative Group. Lancet. 2021;397(10285):1637-1645. 10.1016/S0140-6736(21)00676-0
Diskussion & Kritik
Confirmed REMAP-CAP signal; add tocilizumab in rapidly worsening, CRP-high patients on steroids.